Phaseline

Companies › Epics Therapeutics

Epics Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Nov 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
EP102
METTL3 modulator
METTL3Phase 1Advanced Solid Tumor (Phase 1)Nov 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07163325EP102Phase 1Advanced Solid Tumor (Phase 1)OncologyNov 2027

Targets

METTL3 (1)

Companies with the same targets

STORM Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.